Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > BUSINESS
BUSINESS
- Shift to Specialty - 4: Ceolia Pharma Aims to Be Single-Source Provider in Field of ENT
October 28, 2015
- Jardiance Cardiovascular Data Boon for Japan’s Floundering SGLT-2 Inhibitor Space?
October 26, 2015
- Lilly Joins NCC’s SCRUM-Japan Genomic Screening Project
October 26, 2015
- GSK to Transfer 3 Oncology Products to Novartis in Japan in November
October 26, 2015
- Sandoz Looking to Emerge as Top Foreign Generic Maker in Japan in 5 Years
October 23, 2015
- Chugai to Build New Antibody API Manufacturing Plant
October 23, 2015
- Shift to Specialty – 3: Meiji Seika Pharma to Focus Pipeline, Optimize Sales Force
October 23, 2015
- Belsomra Most Promoted Drug for 2 Months on End: Anterio Ranking
October 21, 2015
- Development of Osteoporosis Drugs in Homestretch, Odanacatib’s US Filing Expected by Year-End
October 21, 2015
- Shift to Specialty – 2: Santen Invests in the Future Over Present Profits
October 21, 2015
- Kowa Seeks Japan Approval of Livalo Successor Pemafibrate
October 20, 2015
- Daiichi Sankyo to Shed 1,000 Jobs in US
October 20, 2015
- Shift to Specialty - 1: Drug Makers Urged to Retool Strategies amid Govt Pressure, Dismal Biz Environment
October 19, 2015
- Eisai, Ajinomoto Link Arms to Create Leading Specialty Pharma for GI Disease
October 16, 2015
- MSD Files Allergy Drug Desloratadine in Japan
October 16, 2015
- Eisai’s GI Disease Biz to Integrate with Ajinomoto Pharma
October 15, 2015
- Plavix Retains Top Slot in FY2014 Japan Drug Sales Ranking: Jiho Tally
October 14, 2015
- Toyama Chemical Licenses RA Drug to Turkish Firm
October 14, 2015
- Astellas Gains Worldwide Rights to Next-Gen DNA Vaccines
October 13, 2015
- (PRESS RELEASE) Shionogi to Spin Off Consumer Healthcare Biz Next Year
October 13, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…